高コレステロール血症治療市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、治療タイプ別、エンドユーザー別、地域別、競合別、2020-2030F

高コレステロール血症治療の世界市場規模は、2024年に213億8,000万米ドルとなり、2030年には338億1,000万米ドルに達すると予測され、予測期間中の年間平均成長率（CAGR）は7.91％で拡大します。

この成長軌道は、心血管疾患の有病率の増加と、コレステロール値の上昇と診断される世界人口の増加に大きく起因しています。

不健康な食生活、座りがちなライフスタイル、遺伝的素因は、高コレステロール血症の罹患率増加の主な要因のひとつです。このような状況が、効果的な治療ソリューションへの需要を高めています。LDL（低比重リポ蛋白）コレステロールの上昇に伴う健康リスク（心臓発作、脳卒中、末梢動脈疾患など）に対する一般市民の意識の高まりは、早期診断と迅速な治療介入の重要性を強調しています。

さらに、官民双方のヘルスケア・イニシアチブからの強力な支援により、スクリーニング・プログラムが拡大され、定期的なコレステロール検査が推奨されるようになりました。こうしたプログラムは、個人が積極的に医師の指導を受け、適切な治療法を選択することを促しています。

市場促進要因

高コレステロール血症の有病率の上昇

市場の課題

高い治療費

市場動向

医薬品研究の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の高コレステロール血症治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患の種類別（遺伝性高コレステロール血症、後天性高コレステロール血症）
  • 治療の種類別（スタチン、PCSK9阻害剤、エゼチミブ、胆汁酸吸着剤、ナイアシン、ベンペド酸、その他）
  • エンドユーザー別（病院、専門心臓センター、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の高コレステロール血症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の高コレステロール血症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の高コレステロール血症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の高コレステロール血症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの高コレステロール血症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Amgen Inc
• Amryt Pharma plc
• AstraZeneca Plc.
• Regeneron Pharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Teva Pharmaceutical Industries Ltd.
• Cipher Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Limited

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Hypercholesterolemia treatment market was valued at USD 21.38 billion in 2024 and is projected to reach USD 33.81 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.91% during the forecast period. This growth trajectory is largely attributed to the increasing prevalence of cardiovascular diseases and a rising global population diagnosed with elevated cholesterol levels.

Unhealthy dietary habits, sedentary lifestyles, and genetic predispositions are among the key factors contributing to the growing incidence of hypercholesterolemia. These conditions are fueling demand for effective treatment solutions. Increased public awareness regarding the health risks associated with elevated LDL (low-density lipoprotein) cholesterol-such as heart attacks, strokes, and peripheral arterial disease-has underscored the importance of early diagnosis and prompt therapeutic intervention.

Furthermore, robust support from both public and private sector healthcare initiatives has led to expanded screening programs and greater advocacy for routine cholesterol testing. These programs are encouraging individuals to proactively seek medical guidance and appropriate treatment options.

Market Drivers

Rising Prevalence of Hypercholesterolemia

The global rise in hypercholesterolemia cases is strongly linked to evolving lifestyle and dietary trends. Sedentary routines combined with high intake of saturated fats and processed foods have significantly increased the number of individuals with high cholesterol levels. According to the World Health Organization (WHO), in 2008, the global prevalence of raised total cholesterol among adults stood at 39% (37% among males and 40% among females), highlighting the widespread nature of this health issue.

Additionally, the global population is aging at a rapid pace. The United Nations Department of Economic and Social Affairs projects that the population aged 65 and older will reach 1.5 billion by 2050, up from 703 million in 2019. Aging is associated with a decline in the body's efficiency in metabolizing and regulating cholesterol, thereby increasing vulnerability to hypercholesterolemia.

Market Challenges

High Cost of Treatment

One of the most pressing challenges in the hypercholesterolemia treatment market is the high cost of therapies, which can hinder access to care and negatively impact patient outcomes. As a chronic condition, hypercholesterolemia typically requires long-term treatment, adding to the financial burden on both patients and healthcare systems.

Although several treatment options are available-including statins and newer agents such as PCSK9 inhibitors-their cost can be prohibitively high, especially for patients without comprehensive insurance coverage. This often leads to delayed treatment initiation, suboptimal adherence, and increased risk of cardiovascular complications.

The economic burden is further compounded by healthcare disparities, particularly among low-income populations who may struggle to afford necessary medications and follow-up care. Consequently, these financial obstacles contribute to unequal access to care and exacerbate existing public health challenges.

Healthcare systems and insurers also face strain from the high cost of providing widespread access to advanced cholesterol-lowering therapies. This pressure may result in limitations on coverage, reduced treatment availability, and compromised quality of care.

Market Trends

Advancements in Pharmaceutical Research

Innovations in pharmaceutical research are significantly advancing the global hypercholesterolemia treatment landscape. While statins have long served as the standard of care, recent developments have introduced novel therapeutic options that are reshaping the market.

Among the most notable innovations is the emergence of PCSK9 inhibitors, which provide an alternative mechanism for lowering LDL cholesterol, particularly in patients who do not respond adequately to statin therapy. These biologics target a specific protein involved in cholesterol regulation, offering enhanced efficacy for certain patient groups.

Ongoing research is also yielding drugs with improved safety profiles and fewer side effects, addressing concerns associated with traditional therapies such as muscle pain. These developments have led to a broader range of treatment options, improving patient compliance and clinical outcomes.

Key Market Players

• Amgen Inc
• Amryt Pharma plc
• AstraZeneca Plc.
• Regeneron Pharmaceuticals, Inc.
• Novartis Pharmaceuticals Corporation
• Teva Pharmaceutical Industries Ltd.
• Cipher Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Limited

Report Scope:

In this report, the Global Hypercholesterolemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hypercholesterolemia Treatment Market, By Disease Type:

• Genetic Hypercholesterolemia
• Acquired Hypercholesterolemia

Hypercholesterolemia Treatment Market, By Treatment Type:

• Statins
• PCSK9 Inhibitors
• Ezetimibe
• Bile Acid Sequestrants
• Niacin
• Bempedoic Acid
• Others

Hypercholesterolemia Treatment Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Hypercholesterolemia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hypercholesterolemia Treatment Market.

Available Customizations:

Global Hypercholesterolemia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hypercholesterolemia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Genetic Hypercholesterolemia, Acquired Hypercholesterolemia)
  • 5.2.2. By Treatment Type (Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin, Bempedoic Acid, Others)
  • 5.2.3. By End User (Hospitals, Specialty Cardiac Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Hypercholesterolemia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hypercholesterolemia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Hypercholesterolemia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Hypercholesterolemia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End User

7. Europe Hypercholesterolemia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Hypercholesterolemia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Hypercholesterolemia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Hypercholesterolemia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Hypercholesterolemia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Hypercholesterolemia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Hypercholesterolemia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Hypercholesterolemia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Hypercholesterolemia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Hypercholesterolemia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Hypercholesterolemia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Hypercholesterolemia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End User

9. South America Hypercholesterolemia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Hypercholesterolemia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Hypercholesterolemia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Hypercholesterolemia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Hypercholesterolemia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Hypercholesterolemia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Hypercholesterolemia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Hypercholesterolemia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Amgen Inc
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Amryt Pharma plc
• 15.3. AstraZeneca Plc.
• 15.4. Regeneron Pharmaceuticals, Inc.
• 15.5. Novartis Pharmaceuticals Corporation
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Cipher Pharmaceuticals Inc.
• 15.8. Pfizer Inc.
• 15.9. Merck & Co., Inc.
• 15.10. Sun Pharmaceutical Industries Limited

16. Strategic Recommendations

17. About Us & Disclaimer